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ABSTRACT
Purpose: To examine the relationship between body mass index (BMI) and the risk of stage ≥3 chronic kidney
disease (CKD) in a general Japanese population.
Methods: A total of 105 611 participants aged 40–79 years who completed health checkups in Ibaraki Prefecture,
Japan, and were free of CKD in 1993 were followed-up through 2006. Stage ≥3 CKD was deﬁned by an estimated
glomerular ﬁltration rate <60mL/min/1.73m2 reported during at least 2 successive annual surveys or as treatment for
kidney disease. Hazard ratios (HRs) for the development of stage ≥3 CKD relative to the BMI categories were
calculated using the Cox proportional hazards regression model, which was adjusted for possible confounders and
mediators.
Results: During a mean follow-up of 5 years, 19 384 participants (18.4%) developed stage ≥3 CKD. Compared to a
BMI of 21.0–22.9 kg/m2, elevated multivariable-adjusted HRs were observed among men with a BMI ≥23.0 kg/m2
and women with a BMI ≥27.0 kg/m2. Signiﬁcant dose-response relationships between BMI and the incidence of stage
≥3 CKD were observed in both sexes (P for trend <0.001).
Conclusions: Obesity was associated with the risk of developing stage ≥3 CKD among men and women.
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INTRODUCTION
Chronic kidney disease (CKD) is a major public health
problem. In Japan, CKD affects 13.3 million adults.1 With
the increasing incidence of hypertension and type 2 diabetes
and the aging of the Japanese population, the number of
individuals with CKD will likely continue to increase. CKD
is recognized as an independent risk factor for myocardial
infarction and cardiovascular mortality and can result in
signiﬁcant morbidity, mortality, and increased medical costs.2
Obesity is also a major public health issue, and its
prevalence has been increasing worldwide. Obesity is
associated with the development of many cardiovascular
disease (CVD) risk factors, including type 2 diabetes
mellitus,3,4 hypertension,5,6 dyslipidemia,7 and CKD.8
Prospective cohort studies have revealed the longitudinal
relation between body mass index (BMI) and the risk of
moderate CKD. A greater baseline BMI was associated with
an increased risk of stage ≥3 CKD in the Physician’s
Health Study,9 the Hypertension Detection and Follow-Up
Program,10 and the Framingham Heart Study.11 Because
treatment of long-term CKD is costly, the best approach is
to reduce the incidence of stage ≥3 CKD or prevent it entirely.
Examining the modiﬁable risk factors for stage ≥3 CKD,
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such as obesity, is important because of the public health
implications.
A relationship between obesity and the risk of stage ≥3
CKD in Japanese participants has been reported.12 However,
not enough information was presented to examine the dose-
response relationship between obesity and the risk of CKD
(ie obesity was only considered as dichotomous data);
consequently, the dose-response relationship in Japanese
individuals remains unclear. An examination of the CKD
risk using more-detailed BMI categories in a large cohort is
warranted. Additionally, no studies have considered the age-
speciﬁc relationship between BMI and the development of
stage ≥3 CKD. Further research on this issue may help
ofﬁcials implement more effective public health and clinical
efforts aimed at the primary prevention of CKD. The purpose
of our study was to examine the dose-response relationship
between BMI and the development of stage ≥3 CKD in a
general Japanese population.
METHODS AND PROCEDURES
Study population
The study population consisted of 194 333 individuals (63 865
men and 130 468 women) aged 40–79 years who were
living in Ibaraki Prefecture, Japan. These individuals had
participated in community-based annual health checkups in
1993 (as part of the Ibaraki Prefectural Health Study), which
were conducted by the local governments in accordance with
the Law of Health and Medical Services for the Elderly. The
Ibaraki prefectural government collected data from the local
governments, and personal information was removed to
ensure anonymity. We excluded 18 939 patients (2367 men
and 16 572 women) because of incomplete data, 10 075
individuals (4101 men and 5974 women) because of a history
of CVD, and 10 491 individuals (3615 men and 6876 women)
because of the presence of stage ≥3 CKD and/or ongoing
treatment for CKD. We further excluded 48 864 individuals
(17 999 men and 30 865 women) who failed to participate in
the 1994 survey, thereby ensuring that all of the participants
were followed for at least one year.
Ultimately, the study included 105 611 participants (35 738
men and 69 873 women). These participants were followed by
annual examinations until a diagnosis of stage ≥3 CKD,
withdrawal from the repeated examinations, or the end of
2006, whichever occurred ﬁrst. The Ibaraki Epidemiology
Study Union Ethics Review Committee approved the protocol
for this cohort study.
Measurements
Kidney function was assessed using the estimated glomerular
ﬁltration rate (eGFR). The eGFR was calculated using the new
Japanese abbreviated prediction equation,13 modiﬁed from
the Modiﬁcation of Diet in Renal Disease (MDRD) Study,14
as recommended by the Japanese Society of Nephrology:
eGFR ðmL=½min1:73m2Þ
¼ ½194 ðserum creatinine ½mg=dLÞ1:094
 ðageÞ0:287  0:739 ðfor women onlyÞ
According to Levey et al, stage ≥3 CKD is deﬁned as the
presence of kidney damage or an eGFR <60mL/min/1.73m2
reported at least twice in successive annual surveys.15
Serum creatinine level was measured using the Jaffe method
with an automated analyzer (Hitachi 7350; Hitachi, Tokyo,
Japan, or RX-30; Nihon Denshi, Tokyo, Japan) in 1993–2003;
in 2004–2006, it was measured using the enzyme method with
an automated analyzer (Hitachi 7770; Hitachi). The coefﬁcient
of validation for creatinine value was 0.61%. Serum creatinine
measurements from 1993–2003 were converted to the value
obtained in the enzyme method using the following equation:
serum creatinine by enzyme method ðmg=dLÞ
¼ 0:9915 serum creatinine by the Jaffe method ðmg=dLÞ
 0:211
The serum creatinine values measured using the enzyme
method and the serum creatinine values measured using the
Jaffe method were then converted to the enzyme method
from the same subjects at the same point in time, and the
comparability between them was found to be excellent
(r = 0.99, P < 0.001). Proteinuria was deﬁned as a urinary
protein excretion of 1+ or more by dipstick test (Ames
Hemacombisticks; Bayer-Sankyo Ltd., Tokyo, Japan).
The patients’ height in sock feet and weight in light clothing
were measured at baseline. BMI was calculated as the weight
in kilograms divided by the height in meters squared (kg/m2).
We measured the following cardiovascular risk factors:
serum total cholesterol, serum high-density-lipoprotein (HDL)
cholesterol, serum triglyceride, plasma glucose, blood
pressure, use of medications, cigarette smoking, and typical
alcohol intake. Blood samples were drawn into two
polyethylene terephthalate tubes from seated participants;
one tube contained an accelerator, while the other con-
tained sodium ﬂuoride and ethylenediaminetetraacetic acid.
Overnight fasting (≥8 h) was not mandatory. The serum total
cholesterol and serum triglyceride levels were measured using
the enzyme method with the RX-30 device in 1993–1995,
the H7350 device in 1996–2003, and the H7700 device in
2004–2006. The HDL cholesterol levels were measured using
the phosphotungstic acid magnesium method with an MTP-32
device (Corona Electric, Ibaraki, Japan) in 1993–1995,
the selective inhibition method with the H7350 device in
1996–2003, and the H7700 device in 2004–2006.
Dyslipidemia was deﬁned as triglycerides ≥1.7mmol/L,
HDL cholesterol <1.036mmol/L, or as the patient being
prescribed medication for dyslipidemia treatment.
The blood glucose level was measured using the glucose
oxidase electrode method with a GA1140 device (Kyoto
Daiichi Kagaku, Kyoto, Japan) in 1993–1996, the enzyme
method with a H7170 device (Hitachi) in 1997–2003, and
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the H7700 device in 1994–2006. The participants were
considered diabetic if they had a plasma glucose of
≥6.1mmol/L in a fasted state or ≥7.8mmol/L in a non-
fasted state, or if they were being treated for diabetes mellitus.
The laboratory participated in external standardization and
successfully met the criteria for precision accuracy for the
measurement of blood samples, as established by the Japan
Medical Association, the Japanese Association of Medical
Technologists, and the Japan Society of Health Evaluation and
Promotion.
Blood pressure was measured on the right arm of seated
participants who had rested for more than 5min; trained
observers obtained these measurements using a standard
mercury sphygmomanometer in 1993–2004 and an automated
sphygmomanometer in 2005–2006. When the systolic blood
pressure was >150mmHg or the diastolic blood pressure was
>90mmHg, a second measurement was obtained after the
subject took several deep breaths. The lower values, which
were almost always observed during the second measurement,
were used for the analyses. Hypertension was deﬁned as
systolic blood pressure ≥140mmHg, diastolic blood pressure
≥90mmHg, or use of antihypertensive medication. CVD
risk factors were deﬁned as hypertension, dyslipidemia, and
diabetes.
Lastly, we conducted an interview to ascertain the number
of cigarettes smoked per day, the typical weekly alcohol
intake (converted to grams of ethanol per day), and the history
of CVD and CKD.
Statistical analysis
The participants were classiﬁed into the following categories
with regard to their BMI (kg/m2): <18.5; 18.5–20.9;
21.0–22.9; 23.0–24.9; 25.0–26.9; 27.0–29.9; or ≥30.0. To
compare the participants’ physical characteristics according to
the BMI categories, one-way analysis of variance was used for
continuous variables, and a χ2-test was used for categorical
variables. The Cox proportional hazards regression model was
used to calculate hazard ratios (HRs) and the 95% conﬁdence
intervals (CIs) of risk of development of stage ≥3 CKD
relative to the BMI categories in comparison to the reference
group, 21.0–22.9 kg/m2. A BMI of 22 kg/m2 is commonly
set as the optimal body size in Japan.16 The analyses were
stratiﬁed by sex and age groups (40–59 and 60–79 years old).
We used two multivariate-adjusted models. In model one,
covariates included age and the potential confounders of
cigarette smoking (never, former, current [1–19 cigarettes/day
or ≥20 cigarettes/day]) and typical alcohol intake (never,
sometimes, everyday [<56 g/day or ≥56 g/day]). In model two,
potential mediators were added to model one. Potential
mediators included systolic blood pressure, the use of
antihypertensive medication (yes or no), triglyceride level
(log-transformed), serum total cholesterol, serum HDL
cholesterol, the use of lipid medication (yes or no), blood
glucose status (normal [<6.1mmol/L in a fasted state or
<7.8mmol/L in a non-fasted state], borderline [6.1–7.0
mmol/L in a fasted state or 7.8–11.1mmol/L in a non-fasted
state], hyperglycemic [>7.0mmol/L in a fasted state or
>11.1mmol/L in a non-fasted state]), the use of diabetes
medication (yes or no), and proteinuria (yes or no). A P value
<0.05 was regarded as statistically signiﬁcant. The SAS
System for Windows, release 9.3 (SAS Institute Inc., Cary,
NC, USA), was used for all analyses.
RESULTS
Sex-stratiﬁed baseline characteristics of the cardiovascular
risk factors according to our BMI categories are provided in
Table 1. All of the factors, except diabetic medication use in
men and lipid medication use in men and women, were
associated with BMI in both sexes. A higher BMI was linked
with a higher eGFR and a higher prevalence of proteinuria in
both sexes.
Of the 105 611 participants (35 738 men and 69 873
women), 19 384 (18.4%) developed stage ≥3 CKD (5978
men and 13 406 women) over a mean follow-up of 5 years
(4.9 years for men and 5.1 years for women). Table 2 and
Figure show the sex-stratiﬁed HRs for the incidence of stage
≥3 CKD according to BMI category. In both sexes, compared
to a BMI of 21.0–22.9 kg/m2, the age- and potential
confounder-adjusted HRs were higher for the higher BMI
categories (model 1; P for trend <0.001; Table 2). Further,
these results were similar even when adjusted for potential
mediators (model 2; Figure). The HRs of BMI ≥30.0 kg/m2
were markedly higher in men and women (HR 1.60, 95% CI
1.24–2.06 and HR 1.41, 95% CI 1.25–1.60, respectively).
Table 3 shows the sex-stratiﬁed HRs for stage ≥3 CKD by
BMI categories among diabetes-free and CVD risk factor-free
patients at baseline. In analyses limited to those free of either
diabetes or of any CVD risk factors, the HRs were higher for
the higher BMI categories (P for trend <0.001).
Table 4 shows the sex- and age-stratiﬁed HRs for the
incidence of stage ≥3 CKD by BMI category compared with
a BMI of 21.0–22.9 kg/m2. In men aged 40–59 years, the
multivariable HRs of BMI ≥30.0 kg/m2 were signiﬁcantly
higher. In men aged 60–79 years, the multivariable HRs of
BMI ≥23.0 kg/m2 were signiﬁcantly higher. In women aged
40–59 years, the multivariable HRs of the overall BMI
categories were not signiﬁcantly associated (P for trend =
0.291). In women aged 60–79 years, the multivariable HRs of
BMI ≥27.0 kg/m2 were signiﬁcantly higher. In both sexes and
age classes, except women aged 40–59 years, a signiﬁcant
dose-response relationship between BMI and the incidence of
stage ≥3 CKD was observed.
DISCUSSION
To the best of our knowledge, this is the ﬁrst cohort study to
demonstrate a dose-response relationship between obesity and
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J Epidemiol 2014;24(6):444-451
the risk of stage ≥3 CKD in a Japanese population. The dose-
response relationship was found in men aged 40–59 and
60–79 years and in women aged 60–79 years. In addition, this
relationship was independent of diabetes and other CVD risk
factors (ie hypertension and dyslipidemia). We also observed
that the risk of stage ≥3 CKD was markedly higher in obese
men and women with a BMI ≥30.0 kg/m2 than in men and
women with a BMI of 21.0–22.9 kg/m2, except in women
aged 40–59 years.
The signiﬁcant relationship observed between BMI and the
incidence of stage ≥3 CKD in our study was consistent with
that observed in previous studies in Caucasian and Asian
Table 1. Baseline characteristics of participants by BMI categories
Gender and baseline variables
Body mass index, kg/m2 P for
difference<18.5 18.5–20.9 21.0–22.9 23.0–24.9 25.0–26.9 27.0–29.9 ≥30.0
Men (n = 35738)
Number of participants 1570 6717 9044 9097 5928 2899 483
Age, years 65.0 (8.8) 62.5 (9.5) 60.8 (9.7) 59.8 (9.7) 59.0 (9.6) 58.9 (9.4) 57.4 (9.4) <0.001
eGFR, mL/(min·1.73m2) 89.9 (18.6) 90.2 (18.4) 88.6 (17.4) 87.1 (17.3) 86.4 (16.8) 85.3 (16.5) 84.4 (16.6) <0.001
Proteinuria, % 2.2 1.7 1.4 1.8 2.2 3.7 6.4 <0.001
Total cholesterol, mmol/L 4.67 (0.81) 4.75 (0.82) 4.94 (0.85) 5.07 (0.86) 5.17 (0.86) 5.21 (0.86) 5.26 (0.86) <0.001
HDL cholesterol, mmol/L 1.63 (0.43) 1.52 (0.40) 1.41 (0.38) 1.30 (0.34) 1.24 (0.31) 1.18 (0.29) 1.14 (0.28) <0.001
Triacylglycerol, mmol/L 1.06 (0.59) 1.21 (0.71) 1.50 (0.91) 1.78 (1.05) 2.05 (1.22) 2.23 (1.31) 2.32 (1.31) <0.001
Blood glucose, mmol/L 6.41 (2.15) 6.37 (2.09) 6.35 (1.98) 6.39 (2.03) 6.45 (2.01) 6.60 (2.26) 6.70 (2.23) <0.001
Systolic blood pressure, mmHg 131.4 (18.2) 133.5 (17.7) 135.1 (16.9) 136.9 (16.6) 138.2 (16.2) 140.8 (16.7) 142.6 (16.2) <0.001
Diastolic blood pressure, mmHg 76.9 (10.6) 78.1 (10.4) 79.7 (10.3) 81.3 (10.3) 82.9 (10.3) 84.6 (10.6) 86.9 (10.9) <0.001
Lipid medication use, % 0.4 0.7 1.2 1.6 1.5 2.0 2.3 0.289
Diabetic medication use, % 3.2 2.6 2.7 3.6 3.7 4.0 3.1 0.361
Antihypertensive medication use, % 12.5 14.5 16.6 19.7 22.4 26.5 32.1 <0.001
Smoking status, % <0.001
Never 18.1 18.7 22.3 24.1 24.4 25.1 28.6
Former 22.2 23.5 27.3 30.3 32.0 33.3 28.8
Current
<20 cigarettes/day 26.4 21.0 16.2 13.8 12.0 10.7 9.7
≥20 cigarettes/day 33.3 36.8 34.2 31.9 31.6 31.0 32.9
Alcohol intake, % <0.001
Never 44.8 35.6 31.9 31.1 31.0 33.4 37.7
Sometimes 10.4 11.1 11.9 13.8 14.6 15.7 14.9
Everyday
<56g/day 41.1 47.5 49.5 49.1 47.3 42.9 38.9
≥56g/day 3.6 5.8 6.7 6.1 7.1 8.1 8.5
Women (n = 69873)
Number of participants 2846 12052 17146 17122 11559 7229 1919
Age, years 60.4 (10.3) 57.5 (9.8) 57.8 (9.3) 58.5 (8.8) 59.4 (8.6) 59.8 (8.4) 59.0 (8.5) <0.001
eGFR, mL/(min·1.73m2) 94.5 (22.0) 96.1 (22.3) 94.2 (21.1) 93.4 (24.9) 91.8 (20.7) 91.4 (20.4) 91.3 (21.0) <0.001
Proteinuria, % 0.9 0.7 0.8 0.9 1.2 1.7 3.3 <0.001
Total cholesterol, mmol/L 5.19 (0.88) 5.27 (0.87) 5.39 (0.89) 5.48 (0.89) 5.55 (0.88) 5.60 (0.91) 5.61 (0.92) <0.001
HDL cholesterol, mmol/L 1.72 (0.40) 1.61 (0.38) 1.51 (0.36) 1.43 (0.34) 1.38 (0.33) 1.35 (0.31) 1.33 (0.31) <0.001
Triacylglycerol, mmol/L 1.07 (0.50) 1.23 (0.65) 1.42 (0.79) 1.61 (0.90) 1.77 (0.96) 1.88 (1.04) 1.94 (0.99) <0.001
Blood glucose, mmol/L 5.90 (1.61) 5.79 (1.40) 5.83 (1.40) 5.96 (1.50) 6.04 (1.52) 6.16 (1.71) 6.35 (2.03) <0.001
Systolic blood pressure, mmHg 126.5 (17.9) 127.2 (17.3) 130.1 (17.0) 132.7 (16.9) 135.4 (16.6) 138.6 (16.8) 141.7 (16.9) <0.001
Diastolic blood pressure, mmHg 73.5 (10.4) 74.7 (10.3) 76.4 (10.1) 78.3 (10.0) 79.9 (10.0) 82.0 (10.0) 84.1 (10.6) <0.001
Lipid medication use, % 1.9 2.2 3.2 3.8 4.2 4.6 4.6 0.988
Diabetic medication use, % 1.3 1.5 1.5 1.9 2.3 2.7 3.2 <0.001
Antihypertensive medication use, % 8.7 10.4 13.8 19.0 23.9 30.6 38.0 <0.001
Smoking status, % <0.001
Never 92.2 95.1 95.5 95.9 95.7 95.2 93.3
Former 0.5 0.4 0.6 0.5 0.6 0.7 0.8
Current
<20 cigarettes/day 4.9 3.2 2.7 2.4 2.5 2.7 3.9
≥20 cigarettes/day 2.3 1.3 1.1 1.3 1.3 1.5 2.1
Alcohol intake, % <0.001
Never 91.3 90.0 90.0 90.7 90.8 91.7 91.5
Sometimes 4.8 5.8 6.3 5.7 5.9 5.1 4.8
Everyday
<56g/day 3.9 4.1 3.6 3.5 3.2 3.1 3.4
≥56g/day — 0.1 0.1 0.1 0.1 0.1 0.3
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; HDL, high-density lipoprotein; SD, standard deviation.
Showing mean (SD) for continuous variables: age, fasting and non-fasting blood glucose, systolic and diastolic blood pressure, total cholesterol,
HDL cholesterol, and triglycerides.
SI conversion factors: to convert blood glucose values to mmol/L, multiply by 0.05551; to convert cholesterols values to mmol/L, multiply by
0.02586; to convert triglycerides values to mmol/L, multiply by 0.01129.
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Table 2. Sex-speciﬁc HRs and 95% CI for stage ≥3 CKD by BMI categories
Sex and body mass
index category
(kg/m2)
Number of
participants
Number of
person-years
Incidence rates
per 1000
person-years
Age-adjusted
HR
95% CI
Multivariate-
adjusted HRa
(model 1)
95% CI
P for
trend
Men
<18.5 1570 7061 20.1 0.76 0.63, 0.90 0.73 0.69, 0.61
18.5–20.9 6717 33677 20.1 0.90 0.82, 0.99 0.89 0.87, 0.81
21.0–22.9 9044 47022 19.9 1 (ref.) 1 (ref.)
23.0–24.9 9097 46973 23.1 1.27 1.16, 1.38 1.27 1.09, 1.17 <0.001
25.0–26.9 5928 30170 22.9 1.38 1.25, 1.52 1.39 1.11, 1.26
27.0–29.9 2899 14091 23.6 1.48 1.31, 1.68 1.48 1.08, 1.30
≥30.0 483 2252 28.4 2.01 1.56, 2.59 1.98 1.24, 1.54
Women
<18.5 2846 14223 19.8 0.75 0.66, 0.85 0.74 0.72, 0.66
18.5–20.9 12052 65680 17.8 0.86 0.80, 0.93 0.86 0.84, 0.80
21.0–22.9 17146 94954 20.1 1 (ref.) 1 (ref.)
23.0–24.9 17122 92420 22.0 1.05 0.99, 1.12 1.05 0.95, 0.99 <0.001
25.0–26.9 11559 61186 24.7 1.11 1.04, 1.19 1.11 0.96, 1.04
27.0–29.9 7229 36348 27.9 1.23 1.14, 1.33 1.23 1.01, 1.14
≥30.0 1919 8760 34.5 1.66 1.47, 1.87 1.64 1.25, 1.45
BMI, body mass index; CI, conﬁdence interval; CKD, chronic kidney disease; HR, hazard ratio.
aAdjusted for age (years), smoking status (never, ex-, current <20 cigarettes/day, or ≥20 cigarettes/day), and alcohol intake (never, sometimes,
<56g/day, or ≥56g/day).
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Figure. The multivariable-adjusted hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for the development of stage
≥3 chronic kidney disease (CKD) in men and women.
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populations.11,17,18 The Framingham Offspring Study, which
included 2585 participants (mean age, 43 years) who were
followed from 1978–2001 (mean follow-up, 18.5 years),
showed a strong dose-response relationship between baseline
BMI and risk of CKD (deﬁned as eGFR using the MDRD
Study equation: ≤64.25mL/[min·1.73m2] in men and
≤59.25mL/[min·1.73m2] in women).11 The multivariable
odds ratio of CKD was 1.23 (95% CI, 1.08–1.41) per one
standard deviation of approximately 4 kg.11 A Japanese
community-based study, which followed 100 753 individuals
(mean age, 49 years) for 17 years, revealed that a higher BMI
at baseline was associated with an increased risk of end-stage
renal disease in men but not women.18 The multivariable-
adjusted odds ratios of end-stage renal disease were 1.27
(95% CI, 1.21–1.45) in men and 0.95 (95% CI, 0.83–1.09) in
women for each 2 kg/m2 increment of BMI.18 Although these
authors did not examine the association between BMI and the
risk of CKD among older adults, their results in middle-aged
adults are consistent with our ﬁndings.
The association between obesity and stage ≥3 CKD may be
mediated through multiple biological mechanisms, including
hormonal factors, inﬂammation, oxidative stress, and
endothelial dysfunction.19,20 In obese individuals, the rennin-
angiotensin-aldosterone system is commonly activated,21 and
it is a well-coordinated hormonal system that regulates
adrenal, cardiovascular, and kidney function by controlling
the ﬂuid and electrolyte balance. Activation of this system
leads to the development of hypertension via the production
of angiotensin 2, which causes further damage to the
kidneys.22 Estrogen, a sex hormone that is secreted more
in premenopausal women compared with men and post-
menopausal women, decreases the expression of angiotensin
Table 3. Sex-speciﬁc HRs and 95% CIs for stage ≥3 CKD by BMI categories among diabetes-free and CVD risk factor-free at
baseline
Sex and body
mass index
category (kg/m2)
Number of
subjects
Number of
person-years
Incidence rates
per 1000
person-years
Age-adjusted
HR
95% CI
Multivariable
HRc
95% CI
P for
trend
Diabetesa-free
Men
<18.5 1207 5426 19.5 0.73 0.60, 0.90 0.80 0.65, 0.99
18.5–20.9 5352 26978 19.4 0.89 0.79, 0.99 0.94 0.84, 1.05
21.0–22.9 7247 38202 19.9 1 (ref.) 1 (ref.)
23.0–24.9 7255 37952 23.1 1.27 1.15, 1.40 1.21 1.09, 1.33 <0.001
25.0–26.9 4601 23495 23.0 1.38 1.24, 1.55 1.26 1.12, 1.41
27.0–29.9 2227 11013 22.2 1.44 1.25, 1.67 1.24 1.07, 1.44
>30.0 359 1715 29.2 2.02 1.52, 2.69 1.64 1.23, 2.19
Women
<18.5 2492 12512 19.4 0.75 0.65, 0.86 0.80 0.70, 0.92
18.5–20.9 10818 58756 17.3 0.86 0.79, 0.93 0.89 0.82, 0.96
21.0–22.9 15336 85182 19.8 1 (ref.) 1 (ref.)
23.0–24.9 15086 81737 21.4 1.03 0.97, 1.11 1.00 0.93, 1.06 <0.001
25.0–26.9 10024 53502 24.4 1.11 1.03, 1.19 1.04 0.96, 1.11
27.0–29.9 6182 31475 27.2 1.21 1.12, 1.32 1.09 1.00, 1.18
>30.0 1574 7272 33.7 1.65 1.44, 1.89 1.41 1.23, 1.62
CVD risk factorb-free
Men
<18.5 501 2364 11.8 0.63 0.42, 0.95 0.64 0.42, 0.96
18.5–20.9 1815 9989 12.0 0.83 0.65, 1.06 0.84 0.65, 1.08
21.0–22.9 1945 10918 12.4 1 (ref.) 1 (ref.)
23.0–24.9 1528 8402 13.9 1.29 1.01, 1.65 1.30 1.01, 1.67 <0.001
25.0–26.9 757 4007 12.5 1.36 0.98, 1.88 1.30 0.93, 1.81
27.0–29.9 232 1121 16.1 1.85 1.13, 3.03 1.78 1.08, 2.93
>30.0 29 109 9.2 2.20 0.31, 15.75 1.94 0.27, 13.92
Women
<18.5 1304 6802 15.1 0.90 0.72, 1.12 0.92 0.74, 1.15
18.5–20.9 5285 29349 12.0 0.99 0.86, 1.14 1.01 0.87, 1.16
21.0–22.9 6243 36399 11.8 1 (ref.) 1 (ref.)
23.0–24.9 4920 27907 14.0 1.17 1.02, 1.34 1.16 1.01, 1.33 <0.001
25.0–26.9 2509 14196 16.3 1.27 1.08, 1.49 1.21 1.03, 1.42
27.0–29.9 1126 5989 19.2 1.57 1.27, 1.92 1.47 1.2, 1.81
>30.0 222 1111 26.1 2.15 1.47, 3.13 1.98 1.35, 2.89
BMI, body mass index; CI, conﬁdence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; HR, hazard ratio.
aDiabetes is deﬁned as plasma glucose ≥6.1mmol/L in a fasted state or ≥7.8mmol/L in a non-fasted state, or being treated for diabetes mellitus.
bCardiovascular disease risk factors are hypertension, dyslipidemia, and diabetes.
cAdjusted for age (years), systolic blood pressure (mmHg), total cholesterol level (mmol/liter), high-density lipoprotein cholesterol level (mmol/liter),
log-transformed triglyceride level (mmol/liter), proteinuria (yes or no), smoking status (never, ex-, current <20 cigarettes/day, or ≥20 cigarettes/day),
and alcohol intake (never, sometimes, <56g/day, or ≥56g/day).
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type 1 receptors in the vasculature and kidneys23 and reduces
the expression and activity of angiotensin-converting
enzymes.24,25 These biological mechanisms may be under-
lying factors for the signiﬁcant relationship between obesity
and the development of stage ≥3 CKD among middle-aged
women in our study.
The strength of our study is that stage ≥3 CKD was deﬁned
as an eGFR level <60mL/min/1.73m2 reported at more than
two successive annual surveys. Further, all of the blood
samples were measured by the same laboratory, which was
veriﬁed using a validated quality control system.26 However,
there are several limitations. First, we only examined
generalized obesity and not abdominal obesity, because the
measurements of central obesity were not available during the
baseline examination. Second, potential residual confounders
may not have been assessed, such as fat distribution, dietary
lifestyle (ie protein and salt intake), and physical activity.
Third, detailed information on use of medications such as
statins and omega 3-fatty acids was not collected because of
the nature of the community-based health checkup.
Obesity was associated with the risk of developing stage
≥3 CKD among men and older women. Compared with
participants who had a normal BMI (21.0–22.9 kg/m2), those
with a BMI ≥30.0 kg/m2 had a markedly high risk of
developing stage ≥3 CKD. Weight management may be
important for preventing CKD in obese men and women.
ONLINE ONLY MATERIAL
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Table 4. Age and sex-speciﬁc HRs and 95% CIs for stage ≥3 CKD by BMI categories
Sex, age group, and
BMI categories
(kg/m2)
Number of
participants
Number of
person-years
Incidence rates
per 1000
person-years
Age-adjusted
HR
95% CI
Multivariable
HRa
95% CI
P for
trend
Men
Age 40–59 years
<18.5 298 1373 2.9 0.44 0.16, 1.18 0.47 0.17, 1.28
18.5–20.9 1948 10900 4.3 0.63 0.45, 0.88 0.71 0.50, 0.99
21.0–22.9 3310 18194 6.7 1 (ref.) 1 (ref.)
23.0–24.9 3762 20086 9.4 1.41 1.12, 1.77 1.22 0.97, 1.54 0.001
25.0–26.9 2676 14323 8.9 1.34 1.05, 1.72 1.10 0.85, 1.42
27.0–29.9 1384 7130 10.9 1.57 1.18, 2.09 1.21 0.90, 1.63
≥30.0 264 1241 16.9 2.59 1.63, 4.11 1.83 1.14, 2.95
Age 60–79 years
<18.5 1272 5688 24.3 0.77 0.64, 0.92 0.84 0.70, 1.01
18.5–20.9 4769 22777 27.7 0.93 0.84, 1.03 0.99 0.89, 1.10
21.0–22.9 5734 28828 28.3 1 (ref.) 1 (ref.)
23.0–24.9 5335 26887 33.4 1.25 1.13, 1.37 1.18 1.07, 1.30 <0.001
25.0–26.9 3252 15847 35.5 1.39 1.25, 1.55 1.26 1.13, 1.41
27.0–29.9 1515 6961 36.6 1.46 1.27, 1.68 1.22 1.06, 1.41
≥30.0 219 1011 42.5 1.83 1.34, 2.48 1.47 1.08, 2.01
Women
Age 40–59 years
<18.5 1209 6864 6.8 0.91 0.68, 1.23 0.98 0.72, 1.33
18.5–20.9 6611 38770 6.7 0.91 0.78, 1.07 0.96 0.82, 1.12
21.0–22.9 9324 56401 7.7 1 (ref.) 1 (ref.)
23.0–24.9 8808 51514 8.4 1.04 0.91, 1.19 1.00 0.88, 1.15 0.291
25.0–26.9 5436 31685 9.2 1.10 0.95, 1.28 1.02 0.87, 1.18
27.0–29.9 3219 17926 9.5 1.17 0.98, 1.39 1.02 0.85, 1.22
≥30.0 928 4778 11.3 1.46 1.10, 1.94 1.19 0.90, 1.59
Age 60–79 years
<18.5 1637 7359 31.9 0.75 0.65, 0.86 0.81 0.70, 0.93
18.5–20.9 5441 26910 33.9 0.86 0.79, 0.93 0.89 0.82, 0.97
21.0–22.9 7822 38553 38.3 1 (ref.) 1 (ref.)
23.0–24.9 8314 40906 39.1 1.04 0.97, 1.12 1.00 0.93, 1.07 <0.001
25.0–26.9 6123 29501 41.4 1.09 1.01, 1.18 1.02 0.95, 1.10
27.0–29.9 4010 18422 45.8 1.22 1.12, 1.33 1.10 1.00, 1.19
≥30.0 991 3982 62.3 1.67 1.46, 1.90 1.44 1.26, 1.65
BMI, body mass index; CI, conﬁdence interval; CKD, chronic kidney disease; HR, hazard ratio.
aAdjusted for age (years), smoking status (never, ex-, current <20 cigarettes/day, or ≥20 cigarettes/day), alcohol intake (never, sometimes,
<56g/day, or ≥56g/day), fasting status (yes or no), systolic blood pressure (mmHg), antihypertensive medication use (yes or no), total cholesterol
level (mmol/liter), high-density lipoprotein cholesterol level (mmol/liter), log-transformed triglyceride level (mmol/liter), lipid medication use (yes
or no), blood glucose status (normal: <6.1mmol/l during fasting or <7.8mmol/l during nonfasting; border: 6.1–7.0mmol/l during fasting or
7.8–11.1mmol/l during nonfasting; hyperglycemic: 7.0mmol/l during fasting or 11.1mmol/l during nonfasting), diabetes medication use (yes or no),
and proteinuria (yes or no).
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